Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Jae Bock Chung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7447-1193; OpenAlex author ID A5020793272. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 4 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 15

  1. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Co-author DOI 10.1016/j.pan.2025.02.007↗
  2. Lifestyle, body mass index, diabetes, and the risk of pancreatic cancer in a nationwide population-based cohort study with 7.4 million Korean subjects. Co-author DOI 10.1038/s41416-022-01807-5↗
  3. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  4. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. Last author DOI 10.1080/01635581.2016.1250921↗
  5. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  6. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Co-author DOI 10.5009/gnl16526↗
  7. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Co-author DOI 10.1016/j.dld.2015.12.006↗
  8. Visceral Obesity is Associated with Poor Prognosis in Pancreatic Adenocarcinoma. Last author DOI 10.1080/01635581.2016.1134600↗
  9. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.3349/ymj.2016.57.5.1124↗
  10. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Co-author DOI 10.1097/mpa.0000000000000163↗
  11. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.07.064↗
  12. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Co-author DOI 10.3349/ymj.2013.54.3.643↗
  13. Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Respon… Co-author DOI 10.5009/gnl.2013.7.5.611↗
  14. Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer. Co-author PMID 23858557↗
  15. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. Last author DOI 10.1097/mpa.0b013e31822a68bc↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seungmin Bang · 12 shared papers, 2013–2025 · strength 0.89
  2. Si Young Song · 13 shared papers, 2012–2017 · strength 0.68
  3. Seung Woo Park · 12 shared papers, 2013–2017 · strength 0.65
  4. Moon Jae Chung · 12 shared papers, 2013–2017 · strength 0.65
  5. Jeong Youp Park · 12 shared papers, 2013–2017 · strength 0.65
  6. Hee Seung Lee · 6 shared papers, 2016–2025 · strength 0.59
  7. Jung Hyun Jo · 4 shared papers, 2014–2025 · strength 0.46
  8. Mi‐Suk Park · 2 shared papers, 2017–2025 · strength 0.34
  9. Seung‐seob Kim · 1 shared paper, 2025 · strength 0.28
  10. Jung Kyu Choi · 1 shared paper, 2022 · strength 0.22
  11. Byung Kyu Park · 1 shared paper, 2022 · strength 0.22
  12. In Rae Cho · 3 shared papers, 2013–2017 · strength 0.16
  13. Bun Kim · 2 shared papers, 2016–2017 · strength 0.12
  14. Sang Hoon Lee · 2 shared papers, 2016–2017 · strength 0.12
  15. Joo Won Chung · 2 shared papers, 2013–2017 · strength 0.12
  16. Chang Moo Kang · 2 shared papers, 2012–2013 · strength 0.07
  17. Woo Jung Lee · 2 shared papers, 2012–2013 · strength 0.07
  18. Se Woo Park · 1 shared paper, 2016 · strength 0.06
  19. Huapyong Kang · 1 shared paper, 2017 · strength 0.06
  20. Do Chang Moon · 1 shared paper, 2016 · strength 0.06
  21. Kyong Joo Lee · 1 shared paper, 2013 · strength 0.04
  22. Semi Park · 1 shared paper, 2013 · strength 0.04
  23. Myeong‐Jin Kim · 1 shared paper, 2012 · strength 0.03
  24. Jinsil Seong · 1 shared paper, 2013 · strength 0.03
  25. Ho Kyoung Hwang · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.